natgillin/translations-raw huggingface dataset:
Personer, som fik flere anfald, blev titreret til den maksimale måldosis på 1.200 mg carbamazepin eller 500 mg zonisamid.
Subjects who experienced a further seizure were titrated to the maximal target dose of 1200 mg carbamazepine or 500 mg zonisamide.
Øges med ugentlige intervaller i trin af 1 mg/kg
Increase at weekly intervals in increments of 1 mg/kg
Hos patienter med nyreinsufficiens var den renale clearance af enkeltdoser af zonisamid positivt korreleret til creatininclearance.
In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance.
Dosisjustering er ikke nødvendig ved administration sammen med andre antiepileptika, herunder CYP3A4-inducere.
There is no need for dose adjustment with any of the AEDs including CYP3A4 inducers.
PVC/PVDC-aluminiumsfolie-blisterpakning i æsker af karton, der indeholder 28, 56, 98 og 196 kapsler.
PVC-PVdC/Aluminium foil blisters in cardboard cartons containing 28, 56, 98 and 196 capsules.
Undertype af anfald (6 måneders anfaldsfri PPpopulation)
Seizure Sub-type (6 month seizure freedom-PP population) All partial
P-glykoprotein-substrat
P-gp substrate
Uge 3 + 4 Uge 5 til 10
Week 1 + 2 Week 3 + 4 Week 5 to 10
Når Zonisamide Mylan seponeres, bør det ske gradvist (se pkt.
When Zonisamide Mylan treatment is to be discontinued, it should be withdrawn gradually (see section 4.4).
Den renale clearance af uomdannet zonisamid er forholdsvis lav (ca. 3,5 ml/min).
Renal clearance of unchanged zonisamide is relatively low (approximately 3.5 ml/min); about 15 - 30 % of the dose is eliminated unchanged.
Faldet i hydrogencarbonat er sædvanligvis lille til moderat (gennemsnitligt ca. 3,5 mEq/l ved døgndoser på 300 mg hos voksne).
The amounts by which bicarbonate is decreased are usually small - moderate (average decrease of approximately 3.5 mEq/l at daily doses of 300 mg in adults); rarely patients can experience more severe decreases.
• Barnet skal undgå voldsom fysisk udfoldelse, navnlig i varmt vejr
• The child must avoid heavy exercise especially when the weather is hot
Ændringer i zonisamidkoncentrationen kan dog forekomme, hvis samtidig behandling med et CYP3A4 inducerende antiepileptikum eller andre lægemidler seponeres, får dosis justeret eller påbegyndes og justering af zonisamid-dosis kan blive nødvendig.
These effects are unlikely to be of clinical significance when zonisamide is added to existing therapy; however, changes in zonisamide concentrations may occur if concomitant CYP3A4-inducing anti-epileptic or other medicinal products are withdrawn, dose adjusted or introduced, an adjustment of the zonisamide dose may be required.
Uge 3 til 5
Week 2 Week 3 to 5
Et syndrom, der består af akut myopi og sekundær glaucoma angulo clauso, er rapporteret hos voksne patienter og pædiatriske patienter, som får zonisamid.
Acute myopia and secondary angle closure glaucoma A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in adult and paediatric patients receiving zonisamide.
Zonisamid bør anvendes med forsigtighed hos voksne patienter, der samtidig behandles med kulsyreanhydrasehæmmere såsom topiramat og acetazolamid, da der foreligger utilstrækkelige data til at udelukke en mulig farmakodynamisk interaktion (se pkt.
Zonisamide should be used with caution in adult patients treated concomitantly with carbonic anhydrase inhibitors such as topiramate and acetazolamide, as there are insufficient data to rule out a possible pharmacodynamic interaction (see section 4.4).
Zonisamide Mylan 25 mg og 50 mg fås i blisterpakninger med 14, 28 eller 56 kapsler, og i perforerede blisterpakninger, der indeholder 14 × 1 kapsler.
Zonisamide Mylan 25 mg and 50 mg are available in blister packs of 14, 28, 56 capsules and perforated unit dose blister packs of 14 x 1 capsules.
Bivirkninger forbundet med zonisamid registreret fra kliniske studier og overvågning efter markedsføring er anført i nedenstående tabel.
Adverse reactions associated with zonisamide obtained from clinical studies and post-marketing surveillance are tabulated below.
Blod og lymfesystem
Blood and lymphatic disorders
Zonisamid Carbamazepin n (ITT-population) Seks måneder uden anfald
Efficacy results for Monotherapy Study 310 Zonisamide Carbamazepine n (ITT population) Six months seizure freedom
Zonisamide Mylan indeholder det aktive stof zonisamid og anvendes mod epilepsi (et antiepileptikum).
What Zonisamide Mylan is and what it is used for Zonisamide Mylan contains the active substance zonisamide, and is used as an antiepileptic medicine.
Kombinationen af zonisamid med andre lægemidler, som kan medføre urolithiasis kan øge risikoen for udvikling af nyresten.
The combination of zonisamide with other medicinal products that may lead to urolithiasis may enhance the risk of developing kidney stones; therefore the concomitant administration of such medicinal products should be avoided.
Obstipation Diarré Dyspepsi Kvalme Opkastning
Constipation Diarrhoea Dyspepsia Nausea Vomiting
- uden CYP3A4induktorer
CYP3A4-inducing agents
- uden CYP3A4induktorer eller ved nedsat nyre- eller leverfunktion
CYP3A4-inducing agents; or with renal or hepatic impairment
Irritabilitet Konfusionstilstande Depression
Agitation Irritability Confusional state
Hver hård kapsel er ca. 19,3 mm lang.
Each hard capsule is approximately 19.3 mm in length.
Kvinder i den fertile alder skal anvende sikker kontraception under behandling med zonisamid og i en måned efter seponering.
Women of childbearing potential must use effective contraception during treatment with zonisamide, and for one month after discontinuation.
Abnorm urinsammensætning
Urine abnormality
1 hård kapsel er ca. 14,4 mm lang.
Each hard capsule is approximately 14.4 mm in length.
6 - 8 mg/kg/dag (én gang dagligt)
6 to 8 mg/kg/day (once a day)
Infektioner og parasitære sygdomme
Infections and infestation
• Sammen med andre antiepileptika til behandling af partielle anfald hos voksne, unge og børn på
• with other antiepileptic medicines to treat seizures in adults, adolescents, and children aged 6 years and above.
Der bør gives medicinsk specialistrådgivning til kvinder i den fertile alder, der behandles med zonisamid.
Specialist advice should be given to women treated with zonisamide who are of childbearing potential.
Alle partielle
Simple partial
Det skal De vide, før De begynder at tage Zonisamide Mylan
What you need to know before you take Zonisamide Mylan
Brug af anden medicin sammen med Zonisamide Mylan Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for nylig.
Other medicines and Zonisamide Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Enkeltdosisblisterpakninger: 14 × 14 hårde kapsler
Unit Dose Blisters: 14 x 1 hard capsules
Øges med 2-ugers intervaller i trin af 1 mg/kg
Increase at twoweekly intervals in increments of 1 mg/kg
Enkeltdosisblisterpakninger: 56 × 1 hårde kapsler
Unit Dose Blisters: 56 x 1 hard capsules
Passende evaluering og monitorering af serum-hydrogencarbonat skal udføres hos denne population (se hele advarslen i pkt.
Appropriate evaluation and monitoring of serum bicarbonate levels should be carried out in this population (see section 4.4 - Metabolic acidosis for full warning; see section 4.8 for incidence of low bicarbonate).
Kvinder i den fertile alder skal anvende sikker kontraception under behandling med zonisamid og i en måned efter seponering (se pkt.
Women of childbearing potential must use effective contraception during treatment with zonisamide and for one month after discontinuation (see section 4.6).
Urinvejsinfektioner Pneumoni
Urinary tract infection Pneumonia
Kosttilskud eller øget fødeindtagelse skal overvejes, hvis patienten ikke tager på i vægt i henhold til vækstkurverne.
A dietary supplement or increased food intake should be considered if the patient is failing to gain weight in accordance with growth charts, otherwise zonisamide should be discontinued.
Agranulocytose Aplastisk anæmi Leucocytose Leukopeni Lymphadenopathi Pancytopeni Trombocytopeni
Agranulocytosis Aplastic anaemia Leucocytosis Leucopoenia Lymphadenopathy Pancytopenia, Thrombocytopenia
Forhøjet kreatininkinase i blodet
Blood creatinine increased
> 4 anfald i løbet af 3-månedersbaselineperioden
PP-population* ITT-population < 4 seizures during 3 month baseline period > 4 seizures during 3 month baseline period
Langtidsvirkningen af vægttab på vækst og udvikling hos børn og unge kendes ikke.
The long term effect of weight loss in the paediatric population on growth and development is unknown.
Når zonisamid seponeres, bør det ske gradvist (se pkt.
When zonisamide treatment is to be discontinued, it should be withdrawn gradually (see section 4.4).
Zonisamid må ikke bruges hos pædiatriske patienter samtidig med andre kulsyreanhydrasehæmmere såsom topiramat og acetazolamid (se pkt.
Zonisamide should not be used as co-medication in paediatric patients with other carbonic anhydrase inhibitors such as topiramate and acetazolamide (see section 4.5).
Uforklarligt udslæt
Unexplained rash
Øget kreatinin i blodet Øget carbamid i blodet Abnorme leverfunktionsprøver
Blood urea increased Liver function tests abnormal
Bivirkninger forbundet med zonisamid, som blev set ved supplerende behandling i kliniske studier og overvågning efter markedsføring
Adverse reactions associated with zonisamide obtained from adjunctive use clinical studies and post-marketing surveillance System Organ
Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt.
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to sulfonamides.
Nyresten er forekommet hos pædiatriske patienter (se den fuldstændige advarsel i pkt.
Kidney stones have occurred in paediatric patients (see section 4.4 Kidney stones for full warning).
Uge 2-8 Patienter, der vejer 20 - 55 kg a
Patients of weight 20 to 55 kga
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger til Lægemiddelstyrelsen:
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
- med CYP3A4induktorer (se pkt.
Adjunctive therapy - with CYP3A4inducing agents (see section 4.5)
Bivirkninger i et randomiseret, kontrolleret studie med monoterapi, der sammenlignede zonisamid med carbamazepin-depotformulering
Adverse reactions in a randomised, controlled monotherapy trial comparing zonisamide with carbamazepine prolonged release System Organ Class (MedDRA terminology†)
Nedsæt risikoen for hedeslag ved at drikke rigeligt med vand og holde Dem i ro.
Reduce the risk of kidney stones by drinking sufficient water - live in a place or are on holiday in a place where the weather is warm.
50 mg/dag (fordelt på 2 doser)
50 mg/day (in two divided doses)
(langvarige eller gentagne krampeanfald).
incontinence), status epilepticus (prolonged or repeated seizures)
• Hvis Deres læge råder Dem til at ophøre med at tage Zonisamide Mylan, vil Deres dosis gradvis blive reduceret for at mindske risikoen for flere anfald.
Do not reduce your dose or stop your medicine unless your doctor tells you to. - If your doctor advises you to stop taking Zonisamide Mylan your dose will be reduced gradually to lower the risk of more seizures.
Svimmelhed Hukommelsesbesvær Døsighed
Ataxia Dizziness Memory impairment Somnolence
Hos pædiatriske patienter (på 6 år og derover) er der vist virkning af zonisamid i et dobbeltblindt, placebokontrolleret studie, der omfattede 207 personer og havde en behandlingsvarighed på op til 24 uger.
Adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adolescent and paediatric patients (aged 6 years and above) In paediatric patients (aged 6 years and above), efficacy has been demonstrated with zonisamide in a double-blind, placebo-controlled study, which included 207 subjects and had a treatment duration of up to 24 weeks.
Zonisamide Mylan tilhører en gruppe lægemidler (sulfonamider), der kan forårsage alvorlige allergiske reaktioner, alvorligt hududslæt og blodsygdomme, som i meget sjældne tilfælde kan være fatale.
Zonisamide Mylan belongs to a group of medicines (sulfonamides) that can cause severe allergic reactions, severe skin rashes, and blood disorders, which very rarely can be fatal.
In-vitro studier viser, at dette ikke påvirkes af tilstedeværelsen af forskellige antiepileptika (dvs. phenytoin, phenobarbital, carbamazepin og natriumvalproat).
Zonisamide is 40 - 50 % bound to human plasma proteins, with in vitro studies showing that this is unaffected by the presence of various antiepileptic medicinal products (i.e., phenytoin, phenobarbitone, carbamazepine, and sodium valproate).
Prægeblæk Shellac
Printing ink Shellac
Zonisamid skal anvendes med forsigtighed hos voksne patienter, der samtidigt behandles med kulsyreanhydrasehæmmere som f.eks. topiramat eller acetazolamid, da der foreligger utilstrækkelige data til at udelukke en farmakodynamisk interaktion (se også pkt.
Zonisamide should be used with caution in adult patients being treated concomitantly with carbonic anhydrase inhibitors such as topiramate or acetazolamide, as there are insufficient data to rule out a pharmacodynamic interaction (see also section 4.4 Paediatric Population and section 4.5).
Alvorlige immunbaserede bivirkninger, som har forbindelse med lægemidler indeholdende en sulfonamidgruppe, omfatter udslæt, allergisk reaktion og alvorlige hæmatologiske sygdomme, inklusive aplastisk anæmi, der i meget sjældne tilfælde kan være fatalt.
Serious immune based adverse reactions that are associated with medicinal products containing a sulfonamide group include rash, allergic reaction and major haematological disturbances, including aplastic anaemia, which very rarely can be fatal.
Et øget tryk i øjet kan, uanset sygdomsårsag, have alvorlige følgevirkninger, hvis det ikke behandles, herunder permanent synstab.
Elevated intraocular pressure of any aetiology, if left untreated, can lead to serious sequelae including permanent vision loss.
• De er ældre, fordi det kan være nødvendigt at justere Deres dosis af Zonisamide Mylan, og De kan have en større risiko for at udvikle en allergisk reaktion, alvorligt hududslæt, hævede fødder og ben samt kløe, når De tager Zonisamide Mylan (se pkt.
If you are younger than 6 years old, Zonisamide Mylan is not recommended for you - are elderly, as your dose of Zonisamide Mylan may need adjusting, and you may be more likely to develop an allergic reaction, severe skin rash, swelling of the feet and legs, and itchiness when taking Zonisamide Mylan (see section 4 Possible Side Effects) - suffer from liver problems, as your dose of Zonisamide Mylan may need adjusting - have eye problems such as glaucoma - suffer from kidney problems as your dose of Zonisamide Mylan may need adjusting - have previously suffered from kidney stones, as you may be at increased risk of developing more kidney stones.
100 mg /dag (fordelt på 2 doser)
100 mg/day (in two divided doses)
1 mg/kg/dag (én gang dagligt)
1 mg/kg/day (once a day)
Zonisamide Mylan tilhører en gruppe lægemidler (sulfonamider), der kan forårsage alvorlige allergiske reaktioner, alvorligt hududslæt og blodsygdomme, som i meget sjældne tilfælde kan være dødelige (se pkt.
Zonisamide Mylan belongs to a group of medicines (sulfonamides) which can cause severe allergic reactions, severe skin rashes, and blood disorders, which very rarely can be fatal (see section 4.
Blisterpakning
BLISTER PACK
Psykiske forstyrrelser
Psychiatric Disorders
Hos rotter sås der et fald i antallet af corpora lutea og implantationssteder ved eksponeringsniveauer, der svarer til den maksimale terapeutiske dosis hos mennesker.
In rats, decreased numbers of corpora lutea and implantation sites were observed at exposure levels equivalent to the maximum therapeutic dose in humans; irregular oestrus cycles and a decreased number of live foetuses were observed at exposure levels three times higher.
Influenzalignende sygdom
Fatigue Influenza-like illness
Perforeret PVC/PVDC-aluminiumsfolie-enkeltdosisblisterpakning i æsker af karton, der indeholder 14 × 1 kapsler.
PVC-PVdC/Aluminium foil perforated unit dose blisters in cardboard cartons containing 14 x 1 capsules.
Nedsat hydrogencarbonat
Decreased bicarbonate
300 mg dagligt (én gang dagligt).
300 mg per day (once a day).
Zonisamid må ikke bruges til pædiatriske patienter sammen med andre lægemidler, som gør patienterne modtagelige for varmerelaterede sygdomme.
Zonisamide should not be used as co-medication in paediatric patients with other medicinal products that predispose patients to heat related disorders; these include carbonic anhydrase inhibitors and medicinal products with anticholinergic activity.
Sort jernoxid (E172)
Black iron oxide (E172) Potassium hydroxide
Alvorlige immunbaserede bivirkninger, som har forbindelse med lægemidler indeholdende en sulfonamidgruppe, omfatter udslæt, allergisk reaktion og alvorlige hæmatologiske sygdomme inklusive aplastisk anæmi, der i meget sjældne tilfælde kan være fatalt (se pkt.
Serious immune based adverse reactions that are associated with medicinal products containing a sulfonamide group include rash, allergic reaction and major haematological disturbances including aplastic anaemia, which very rarely can be fatal (see section 4.4).
Zonisamide Mylan 25 mg hårde kapsler har en lys overdel og en lys underdel, er markeret med ”Z 25” i sort skrift og fyldt med lyst/næsten hvidt pulver.
Zonisamide Mylan 25 mg hard capsules have a white body and a white cap, marked ‘Z 25' in black and contain a white/almost white powder.
• De er undervægtig eller har haft et stort vægttab, fordi Zonisamide Mylan kan betyde, at De taber Dem yderligere.
Reduce the risk of overheating by drinking sufficient water and keeping cool - are underweight, or have lost a lot of weight as Zonisamide Mylan can cause you to lose more weight.
PVC/PVDC-aluminiumsfolie-enkeltdosisblisterpakning i æsker af karton, der indeholder 14, 25 og 56 kapsler.
PVC-PVdC/Aluminium foil blisters in cardboard cartons containing 14, 28 and 56 capsules.
Zonisamide Mylan 100 mg hårde kapsler har en lys overdel og en lys underdel, er markeret med ”Z 100” i sort skrift og fyldt med lyst/næsten hvidt pulver.
Zonisamide Mylan 100 mg hard capsules have a white body and white cap, marked ‘Z 100' in black and contain a white/almost white powder.
• Zonisamide Mylan er beregnet til at blive taget som langtidsbehandling.
If you stop taking Zonisamide Mylan - Zonisamide Mylan is meant to be taken as a long-term medicine.
Zonisamide Mylan 50 mg hårde kapsler har en lys overdel og en lys underdel, er markeret med ”Z 50” i rød skrift og fyldt med lyst/næsten hvidt pulver.
Zonisamide Mylan 50 mg hard capsules have a white body and white cap, marked ‘Z 50' in red and contain a white/almost white powder.
Uge 1+2
Week 1 + 2 Weeks ≥ 3
Perforeret PVC/PVDC-aluminiumsfolie-enkeltdosisblisterpakning i æsker af karton, der indeholder 56 × 1 kapsler.
PVC-PVdC/Aluminium foil perforated unit dose blisters in cardboard cartons containing 56 x 1 capsules.
J. Uriach y Compania S.A. Av. Cami Reial 51-57
Av Cami Reial 51-57
Abdominalsmerter Obstipation Diaré
Abdominal pain Constipation Diarrhoea Dyspepsia Nausea
Zonisamid metaboliseres delvist af CYP3A4 (reduktiv nedbrydning) samt også af N acetyl-transferaser og konjugering med glukoronsyre.
Zonisamide is metabolised partly by CYP3A4 (reductive cleavage), and also by N-acetyl-transferases and conjugation with glucuronic acid; therefore, substances that can induce or inhibit these enzymes may affect the pharmacokinetics of zonisamide:
Pruritus Ekkymose
Pruritus Ecchymosis
Sådan skal De tage Zonisamide Mylan
How to take Zonisamide Mylan
Zonisamide Mylan 25 mg kapsel, hård Zonisamide Mylan 50 mg kapsel, hård Zonisamide Mylan 100 mg kapsel, hård
Zonisamide Mylan 25 mg hard capsules Zonisamide Mylan 50 mg hard capsules Zonisamide Mylan 100 mg hard capsules
• Den anbefalede dosis er på mellem 300 mg og 500 mg.
- The recommended daily dose is between 300 mg and 500 mg. - Some people respond to lower doses.
• Hvis De glemmer at tage en dosis, skal De ikke blive fortvivlet.
If you forget to take Zonisamide Mylan - If you forget to take a dose, don't worry: take the next dose when it is due.
• Tal med lægen eller apotekspersonalet, før De tager Zonisamide Mylan, hvis De er yngre end 12 år, da De kan have en større risiko for nedsat svedproduktion, hedeslag, lungebetændelse og leverproblemer.
- are younger than 12 years old, as you may be at greater risk of decreased sweating, heat stroke, pneumonia and liver problems.
Zonisamide Mylan kan få Deres barn til at svede mindre og blive overophedet.
Zonisamide Mylan can cause your child to sweat less and overheat and if your child is not treated this can lead to brain damage and death.
Antiepileptika
Status epilepticus
Zonisamide Mylan 25 mg kapsel, hård Zonisamide Mylan 50 mg kapsel, hård Zonisamide Mylan 100 mg kapsel, hård zonisamid
Zonisamide Mylan 25 mg hard capsules Zonisamide Mylan 50 mg hard capsules Zonisamide Mylan 100 mg hard capsules zonisamide
Zonisamide Mylan 25 mg og 50 mg hårde kapsler
Zonisamide Mylan 25 mg and 50 mg hard capsules
200 mg/dag (én gang dagligt)
200 mg/day (once a day)
Denne indlægsseddel blev senest ændret den
- This medicine has been prescribed for you only.
• hukommelsestab, dyb bevidstløshed, neuroleptisk malignt syndrom (manglende evne til at bevæge sig, sved, feber, manglende evne til at holde på urin og afføring), status epilepticus
Very rare (may affect up to 1 in 10,000 people): - memory loss, coma, neuroleptic malignant syndrome (inability to move, sweating, fever,
Udslæt
Ataxia
300 mg/dag (én gang dagligt)
300 mg/day (once a day)
• De pludselig får smerter i ryggen eller maven, har smerter ved vandladning (når De tisser) eller bemærker blod i urinen, da dette kan være tegn på nyresten.
A small number of people being treated with anti epileptics such as Zonisamide Mylan have had thoughts of harming or killing themselves- have pain in your muscles or a feeling of weakness, as this may be a sign of abnormal muscle breakdown which can lead to kidney problems - get a sudden pain in your back or stomach, have pain on urinating (passing water) or notice blood in your urine, as this may be a sign of kidney stones - develop visual problems such as eye pain or blurred vision while taken zonisamide.
En gennemsigtig lys overdel og en lys underdel markeret med 'Z 50' i rød skrift, fyldt med lyst/næsten hvidt pulver.
A white opaque body and a white opaque cap, marked ‘Z 50' in red containing white/almost white powder.
Dosis øges med 100 mg med ugentlige intervaller
Increase at weekly intervals in increments of 100 mg
En gennemsigtig lys overdel og en lys underdel markeret med 'Z 100' i sort skrift, fyldt med lyst/næsten hvidt pulver.
A white opaque body and a white opaque cap, marked ‘Z 100' in black containing white/almost white powder.
100 mg/dag (én gang dagligt)
100 mg/day (once a day)
Zonisamide Mylan 100 mg hårde kapsler
Zonisamide Mylan 100 mg hard capsules
Zonisamide Mylan 25 mg og 100 mg, hård kapsel
Zonisamide Mylan 25 mg and 100 mg hard capsules
Amning
Amnesia
Hver kapsel indeholder 100 mg zonisamid.
Each capsule contains 100 mg of zonisamide.
En lys, gennemsigtig underdel og en lys overdel, markeret med 'Z 25' i sort skrift, fyldt med lyst/næsten hvidt pulver.
A white opaque body and a white opaque cap, marked ‘Z 25' in black containing white/almost white powder.
• Startdosis er 50 mg dagligt indtaget i to lige store doser på 25 mg.
When you take Zonisamide Mylan with other antiepileptic medicines: - The starting dose is 50 mg daily taken in two equal doses of 25 mg. - This may be increased by up to 100 mg at intervals of one to two weeks.